ALK Summit 2021: STRONGER TOGETHER. What is Next After Lorlatinib? 4th Generation TKI’s and Beyond Speakers: dr. Ross Camidge, MD, PHD University of Colorado Cancer Center, Dr. Christine Lovly, MD PhD, BA Vanderbilt- Ingram Cancer Center. Moderator(s): Colin Barton, Emily Vennzi. Dr. Ross Camidge and Dr. Christine Lovly speak about the many treatment options that are available NOW if a patient experiences progression on Lorlatinib. Even more exciting, they speak about what's already visible on the horizon for new treatments that could transform our future. WATCH VIDEO
ALK Positive Inc.
Authors: Dr. Ross Camidge and Dr. Christine Lovly